地塞米松
免疫系统
医学
鼻腔给药
药理学
免疫学
人口
鼻粘膜
内科学
环境卫生
作者
Li‐Shang Dai,Bin Liu,Jiangtao Lin,Yongquan Jiang,Yuanyuan Li,Zhibin Ye,Shuang Shen,Yiming Jiang,Yourong Duan,Jiping Li
标识
DOI:10.1186/s12951-024-02306-w
摘要
Abstract Background Allergic rhinitis (AR) is a prevalent immune-related allergic disease, and corticosteroid nasal sprays serve as the primary treatment for this patient population. However, their short duration of efficacy and frequent administration pose challenges, leading to drug wastage and potential adverse effects. To overcome these limitations, we devised a novel approach to formulate DEX-Gel by incorporating dexamethasone (DEX) into a blend of Pluronic F127, stearic acid (SA), and polyethylene glycol 400 (PEG400) to achieve sustained-release treatment for AR. Results Following endoscopic injection into the nasal mucosa of AR rats, DEX-Gel exhibited sustained release over a 14-day period. In vivo trials employing various assays, such as flow cytometry (FC), demonstrated that DEX-Gel not only effectively managed allergic symptoms but also significantly downregulated helper T-cells (T H ) 2 and T H 2-type inflammatory cytokines (e.g., interleukins 4, 5, and 13). Additionally, the T H 1/T H 2 cell ratio was increased. Conclusion This innovative long-acting anti-inflammatory sustained-release therapy addresses the T H 1/T H 2 immune imbalance, offering a promising and valuable approach for the treatment of AR and other inflammatory nasal diseases. Graphical Abstract
科研通智能强力驱动
Strongly Powered by AbleSci AI